---
title: "OGN: Revenue and net income fell as biosimilar growth offset declines in core brands; Sun Pharma deal advances"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294516404.md"
description: "Revenue and net income declined year-over-year, with strong biosimilar growth offset by declines in key women's health and established brands. The company completed a major divestiture, advanced biosimilar collaborations, and received stockholder approval for acquisition by Sun Pharma, with closing expected in early 2027.Original document: Organon & Co. [OGN] SEC 10-Q Quarterly Report — Aug. 4 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-31T12:51:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294516404.md)
  - [en](https://longbridge.com/en/news/294516404.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294516404.md)
---

# OGN: Revenue and net income fell as biosimilar growth offset declines in core brands; Sun Pharma deal advances

Revenue and net income declined year-over-year, with strong biosimilar growth offset by declines in key women's health and established brands. The company completed a major divestiture, advanced biosimilar collaborations, and received stockholder approval for acquisition by Sun Pharma, with closing expected in early 2027.

Original document: Organon & Co. \[OGN\] SEC 10-Q Quarterly Report — Aug. 4 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [OGN.US](https://longbridge.com/en/quote/OGN.US.md)

## Related News & Research

- [Organon Announces Quarterly Dividend | OGN Stock News](https://longbridge.com/en/news/294516961.md)
- [Organon & Co. 2026: Revenue $1.56B, EPS $0.4— 10-Q Summary](https://longbridge.com/en/news/294511535.md)
- [Orographic Financial Advisors LLC Acquires New Holdings in Organon & Co. $OGN](https://longbridge.com/en/news/294494554.md)
- [13:03 ETAdvancing Precision Oncology with Biomarker-driven Strategies and Digital Data Solutions, Upcoming Webinar Hosted by Xtalks](https://longbridge.com/en/news/294540916.md)
- [05:24 ETThreatMark positioned as a Leader in the SPARK Matrix™: Behavioral Biometrics and Device Intelligence Solutions 2026 by QKS Group](https://longbridge.com/en/news/294335348.md)